Safeguard Scientifics Inc (SFES)

[frankie_fillet]

News for ' SFE ' - (Laureate Pharma Announces Manufacturing Agreement With Alopexx
Pharmaceuticals, LLC)


PRINCETON, New Jersey, Apr 10, 2008 (PR Newswire Europe via COMTEX) -- Laureate
To Manufacture Alopexx's Product Candidate -

Laureate Pharma, Inc., a full-service biopharmaceutical development and protein
production company, today announced that it has entered into a cGMP contract
manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the
agreement, Laureate will produce Alopexx's mAb F598 antibody under cGMP
conditions. This antibody is planned for use in clinical trials, and later for
commercial production for the treatment and prevention of Staphylococcus aureus
infections. Terms of the manufacturing agreement were not disclosed.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )

"We are pleased that Alopexx chose Laureate Pharma as their manufacturing
partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will
closely collaborate with the Alopexx team and help them drive their product from
development into the clinic."

"Laureate Pharma has a track record of demonstrated expertise in
biopharmaceutical manufacturing, including capabilities in both clinical and
commercial-grade materials," said Dr. Daniel Vlock, President and CEO of
Alopexx. "We look forward to our partnership with Laureate and advancing our
antibody therapeutics program into the clinic."

About Laureate Pharma, Inc.

Laureate Pharma is a full-service biopharmaceutical development and protein
production company located in Princeton, New Jersey. Laureate Pharma offers
superior bioprocessing services that accelerate new products from development
through production. Laureate provides a wide range of specialized services from
process design and development to full-scale cGMP production, purification,
aseptic filling, testing, validation, analytical services, and regulatory
support. Laureate is focused on two active segments of the biopharmaceutical
industry: monoclonal antibodies and recombinant protein products. Laureate
Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc. (NYSE:
SFE) (www.safeguard.com). For more information, contact Michael Cavanaugh, Vice
President Sales, Marketing, and Business Development at [phone], or
[e-mail] or visit www.laureatepharma.com .

About Alopexx Pharmaceuticals, LLC

Alopexx Pharmaceuticals was founded to develop a promising new treatment for
serious Staphylococcus aureus infections, including those caused by
methicillin-resistant strains known as MRSA. In the past decade MRSA has emerged
as a major public health problem. Due to the increasing volume of antimicrobial
usage around the world, MRSA and many bacteria have become increasingly
resistant to most commonly used antibiotics. mAb F598 is a fully human
monoclonal antibody that has the potential to serve as an alternative to
antibiotics in the fight against MRSA and other S. aureus infections. Unlike
antibiotics, monoclonal antibodies will not lead to the development of bacterial
resistance. The target of the antibody is a carbohydrate on the bacterial
capsule known as PNAG. PNAG has been found to be a critical factor in the
virulence and immune response to MRSA as well as non-MRSA staphylococcal
infections and is also expressed by other bacterial pathogens. Alopexx
Pharmaceuticals, LLC was co-founded by Gerald Pier, PhD and Daniel Vlock, MD.
Its aim is to develop and explore the use of novel therapies for the treatment
and prevention of MRSA and other serious infections. For more information
contact Daniel Vlock, MD at [phone] or [e-mail] or visit
www.alopexx.com .



Web site: http://www.laureatepharma.com

http://www.alopexx.com

http://www.safeguard.com